Conformis along with Bodycad Laboratories and Bodycad USA announced that they have entered into a settlement and license agreement that resolves the patent infringement dispute filed by Conformis in June of 2021. The companies have agreed to an undisclosed amount for the dismissal of all patent litigation between the companies along with a release and license to certain Conformis patents related to patient-specific instrumentation and knee implants.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CFMS:
- Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation
- Conformis sees Q1 product revenue $12M-$13M
- Conformis sees Q4 revenue $17.4M, two est. $13.67M
- Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022
- Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022
